Sanofi CEO promises clearer picture
Article Abstract:
The new Chief Executive Officer, Gerard Le Fur of Sanofi-Aventis S.A. of France is talking up its drug line. The pharmaceutical house is beginning to reveal the potential of its experimental drugs in a bid to create more investor interest and increase its stock price.
Publisher: Dow Jones Publishing Co. (Europe)
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2007
Securities issued, listed, France, Securities, Company securities, SNY, Sanofi-Aventis S.A., Financial report, Le Fur, Gerard
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2007
User Contributions:
Comment about this article or add new information about this topic:
Betting $10 billion on generics, Novartis seeks to inject growth
Article Abstract:
Chief Executive Officer Daniel Vasella, Novartis AG of Switzerland is promoting both its generic and brand name operations. The generics market is forecast to be worth $100 billion by 2010 and Novartis AG expects to have 10 percent market share.
Publisher: Dow Jones Publishing Co. (Europe)
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2006
Switzerland, Novartis AG, NVTSY, Vasella, Daniel
Publication Name: Wall Street Journal. Europe
Subject: Business, international
ISSN: 0921-9986
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
Subjects list: Management, Pharmaceutical industry, Company business management, Company overview
Similar abstracts:
- Abstracts: SkyePharma attracts interest. AstraZeneca is on prowl outside its own lab walls. Big drug makers take a pass on Serono
- Abstracts: Swisscom gets approval for foreign takeovers. Alder steps down from Swisscom after Eircom row. Swisscom eases plans to invest in foreign firms
- Abstracts: Bring on the ads. The fickle beer consumer. Make way for the 'ad pod'
- Abstracts: FDA panel votes to return MS drug Tysabri to market. Sanofi withdraws obesity-drug application in U.S. 'Miracle' obesity pill looks less miraculous: repeated FDA delays, European restrictions ail Sanofi's Acomplia
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.